These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17407564)

  • 1. Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity.
    O'Connor EB; Cotter PD; O'Connor P; O'Sullivan O; Tagg JR; Ross RP; Hill C
    BMC Microbiol; 2007 Apr; 7():24. PubMed ID: 17407564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations.
    Morgan SM; O'connor PM; Cotter PD; Ross RP; Hill C
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2606-11. PubMed ID: 15980326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities.
    Field D; Collins B; Cotter PD; Hill C; Ross RP
    J Mol Microbiol Biotechnol; 2007; 13(4):226-34. PubMed ID: 17827973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Each peptide of the two-component lantibiotic lacticin 3147 requires a separate modification enzyme for activity.
    McAuliffe O; Hill C; Ross RP
    Microbiology (Reading); 2000 Sep; 146 ( Pt 9)():2147-2154. PubMed ID: 10974102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene.
    Navaratna MA; Sahl HG; Tagg JR
    Infect Immun; 1999 Aug; 67(8):4268-71. PubMed ID: 10417203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
    Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
    Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aureus C55.
    Navaratna MA; Sahl HG; Tagg JR
    Appl Environ Microbiol; 1998 Dec; 64(12):4803-8. PubMed ID: 9835565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147.
    Ryan MP; Jack RW; Josten M; Sahl HG; Jung G; Ross RP; Hill C
    J Biol Chem; 1999 Dec; 274(53):37544-50. PubMed ID: 10608807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous expression of lacticin 3147 in Enterococcus faecalis: comparison of biological activity with cytolysin.
    Ryan MP; McAuliffe O; Ross RP; Hill C
    Lett Appl Microbiol; 2001 Feb; 32(2):71-7. PubMed ID: 11169046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR.
    McAuliffe O; O'Keeffe T; Hill C; Ross RP
    Mol Microbiol; 2001 Feb; 39(4):982-93. PubMed ID: 11251818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design.
    Cotter PD; Deegan LH; Lawton EM; Draper LA; O'Connor PM; Hill C; Ross RP
    Mol Microbiol; 2006 Nov; 62(3):735-47. PubMed ID: 17076667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-immunity and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147.
    Draper LA; Grainger K; Deegan LH; Cotter PD; Hill C; Ross RP
    Mol Microbiol; 2009 Feb; 71(4):1043-54. PubMed ID: 19183281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial effect and in vivo preventive and therapeutic effects of partially purified lantibiotic lacticin NK34 against infection by Staphylococcus species isolated from bovine mastitis.
    Kim SY; Shin S; Koo HC; Youn JH; Paik HD; Park YH
    J Dairy Sci; 2010 Aug; 93(8):3610-5. PubMed ID: 20655430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity.
    Martin NI; Sprules T; Carpenter MR; Cotter PD; Hill C; Ross RP; Vederas JC
    Biochemistry; 2004 Mar; 43(11):3049-56. PubMed ID: 15023056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis and characterization of lacticin Q, a novel bacteriocin belonging to a new family of unmodified bacteriocins of gram-positive bacteria.
    Fujita K; Ichimasa S; Zendo T; Koga S; Yoneyama F; Nakayama J; Sonomoto K
    Appl Environ Microbiol; 2007 May; 73(9):2871-7. PubMed ID: 17351096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure of the lantibiotic lacticin 481 produced by Lactococcus lactis: location of the thioether bridges.
    van den Hooven HW; Lagerwerf FM; Heerma W; Haverkamp J; Piard JC; Hilbers CW; Siezen RJ; Kuipers OP; Rollema HS
    FEBS Lett; 1996 Aug; 391(3):317-22. PubMed ID: 8764998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics.
    Holo H; Jeknic Z; Daeschel M; Stevanovic S; Nes IF
    Microbiology (Reading); 2001 Mar; 147(Pt 3):643-651. PubMed ID: 11238971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the lacticin 481 operon: the Lactococcus lactis genes lctF, lctE, and lctG encode a putative ABC transporter involved in bacteriocin immunity.
    Rincé A; Dufour A; Uguen P; Le Pennec JP; Haras D
    Appl Environ Microbiol; 1997 Nov; 63(11):4252-60. PubMed ID: 9361411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure, organization, and expression of the lct gene for lacticin 481, a novel lantibiotic produced by Lactococcus lactis.
    Piard JC; Kuipers OP; Rollema HS; Desmazeaud MJ; de Vos WM
    J Biol Chem; 1993 Aug; 268(22):16361-8. PubMed ID: 8344922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147.
    Deegan LH; Suda S; Lawton EM; Draper LA; Hugenholtz F; Peschel A; Hill C; Cotter PD; Ross RP
    Microb Biotechnol; 2010 Mar; 3(2):222-34. PubMed ID: 21255322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.